HDAC Inhibitors for Treatment of PAH

• Pulmonary arterial hypertension (PAH) has limited treatment options with 40-50% mortality within 3 years of diagnosis. It remains a critical unmet medical need. The global market for PAH is expected to grow to over $3.5 billion by 2016.
• Augmentation of MEF2 activity holds a potential therapeutic value in PAH.
• HDAC IIa inhibition enhances MEF2 activity, shows efficacy in rodent models of PAH.
• Selective HDAC inhibition should avoid the potential adverse effects of broad spectrum HDAC inhibition in PAH.
• Reference: Kim et al. (2015) Circulation.
• Filed and Issued Patents: 9340787; 20140155459
• Innovator: Hyung Chun, M.D.